Pull to refresh
Logo
Daily Brief
Following Why Sign Up
First CLDN18.2 antibody-drug conjugate reaches regulatory review for gastric cancer

First CLDN18.2 antibody-drug conjugate reaches regulatory review for gastric cancer

New Capabilities

Innovent's IBI343 met its Phase 3 goal in previously treated patients, and China's drug regulator accepted the filing under priority review.

June 4th, 2026: Phase 3 meets its goal; China accepts filing

Overview

Updated Jun 4

Advanced gastric cancer that returns after treatment usually kills within about six months. On June 4, 2026, Chinese biotech Innovent Biologics said its drug had slowed that clock in a late-stage trial.

The drug, arcotatug tavatecan, targets a protein called CLDN18.2 and ferries chemotherapy straight into tumor cells. It is the first drug of this design to reach a regulator. China's drug agency has agreed to review it for approval.

Why it matters

Patients out of options for advanced gastric cancer may soon get a treatment that buys more time before the disease grows again.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

~6 mo
Typical survival after first-line treatment fails
Advanced gastric cancer patients often live about six months once initial therapy stops working.
29%
Tumor response rate in Phase 1
Share of CLDN18.2-high patients whose tumors shrank at the recommended dose.
5.5 mo
Median time without disease growth (Phase 1)
Measured in CLDN18.2-high gastric cancer patients before the larger trial.
$11.4B
Maximum value of Takeda licensing deal
Takeda's October 2025 deal for rights to the drug outside Greater China, including milestones.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

Hui Zhou
Hui Zhou
Chief R&D Officer, Oncology, Innovent Biologics
Leading the drug's development program
 Kohei Shitara
Kohei Shitara
Gastrointestinal oncologist and trial investigator
Reported the trial's safety and efficacy findings

Organizations Involved

Innovent Biologics
Innovent Biologics
Biotechnology company
Developer of arcotatug tavatecan (IBI343)

A Suzhou-based Chinese drugmaker that developed the first CLDN18.2 antibody-drug conjugate to reach regulatory review.
National Medical Products Administration (NMPA)
National Medical Products Administration (NMPA)
Government regulatory agency
Reviewing the drug application

China's drug and device regulator, the rough equivalent of the U.S. Food and Drug Administration.
Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
Global biopharmaceutical company
Global partner outside Greater China

Japan's largest drugmaker, which licensed rights to the drug everywhere outside Greater China.
Astellas Pharma
Astellas Pharma
Pharmaceutical company
Maker of the first approved CLDN18.2 drug

Japanese drugmaker behind Vyloy, the first CLDN18.2-targeted therapy to win approval.

Timeline

October 2022 June 2026

6 events Latest: June 4th, 2026 · 3 months ago
Tap a bar to jump to that date

  1. Phase 3 meets its goal; China accepts filing

    Latest Regulatory

    An interim analysis shows the drug delays disease growth. China's NMPA accepts the application under priority review.

  2. Takeda licenses the drug

    Deal

    Takeda pays $1.2 billion upfront for rights outside Greater China, in a deal worth up to $11.4 billion.

  3. Phase 1 results published in Nature Medicine

    Data

    Across 116 patients, the drug shrank tumors in 29% of CLDN18.2-high cases with little gut toxicity.

  4. FDA approves the first CLDN18.2 drug

    Regulatory

    Astellas's Vyloy becomes the first treatment aimed at CLDN18.2, validating the target IBI343 also hits.

  5. Phase 3 trial launches

    Trial

    The international G-HOPE-001 study opens in China and Japan, testing the drug against investigator-chosen therapy.

  6. First patient dosed in Phase 1

    Trial

    Innovent begins testing IBI343 in advanced gastric and gastroesophageal junction cancer patients.

Scenarios

1

China approves the first CLDN18.2 antibody-drug conjugate

Likely Resolves by Q2 2027

Discussed by: Innovent guidance and oncology trade press (BioSpace, OncLive)

The NMPA already put the filing on its faster track, which it reserves for serious diseases with few options. The interim trial data met the goal that usually carries an application. If the full review finds no safety surprises, approval in China for previously treated patients is the most direct next step.

2

Trial confirms patients live longer overall

Uncertain Resolves by End of 2027

Discussed by: Trial investigators, expected at ASCO or ESMO oncology meetings

The study has two main goals: delaying disease growth and extending overall survival. The interim analysis met the first. Overall survival data take longer to mature. A confirmed survival benefit would strengthen the case far beyond China and shape how doctors rank the drug against existing options.

3

Takeda files the drug in the U.S. or Europe

Possible Resolves by End of 2027

Discussed by: Takeda and Innovent partnership disclosures

Takeda holds rights everywhere outside Greater China and would run any Western filing. The China data alone may not satisfy the FDA or the European Medicines Agency, which often want trials including their own patients. Takeda's timing depends on whether the existing data clear that bar or it needs to gather more.

4

A rival CLDN18.2 conjugate catches up

Possible Resolves by End of 2027

Discussed by: Analysts tracking the CLDN18.2 drug field (GlobeNewswire market reports)

Innovent is first, but it is not alone. Several companies, including AstraZeneca's partner LaNova, are developing their own CLDN18.2 antibody-drug conjugates. If one of them reaches a regulator within roughly 18 months, Innovent's first-mover lead narrows and the competition for doctors and patients begins sooner.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

2010

Herceptin's ToGA trial in gastric cancer (2010)

The ToGA trial showed trastuzumab, branded Herceptin, helped gastric cancer patients whose tumors carried the HER2 protein. It was the first time a biomarker-defined targeted drug worked in this cancer. Roughly one in five gastric tumors qualified.

Then

Regulators approved trastuzumab for HER2-positive gastric cancer, adding a targeted option to chemotherapy.

Now

Testing tumors for a molecular marker before treatment became standard practice in gastric cancer.

Why this matters now

It set the template Innovent now follows: find a protein on the tumor, select patients who carry it, then aim a drug at it.

January 2021

Enhertu's gastric cancer approval (2021)

The FDA approved trastuzumab deruxtecan, sold as Enhertu, for HER2-positive gastric cancer after earlier treatments failed. Enhertu is an antibody-drug conjugate, the same design as Innovent's drug. It pairs a targeting antibody with a chemotherapy payload.

Then

Patients who had run out of options gained a treatment that shrank tumors more often than chemotherapy.

Now

It proved the conjugate design could beat standard chemotherapy in gastric cancer, fueling a wave of similar drugs.

Why this matters now

Enhertu showed the exact mechanism Innovent uses can work in this disease, lowering the technical doubt around IBI343.

October 2024

Vyloy becomes the first CLDN18.2 drug (2024)

The FDA approved Astellas's Vyloy, an antibody aimed at CLDN18.2, for newly diagnosed advanced gastric cancer. It was the first drug to target this protein. About 38% of gastric tumors carry enough of it to qualify.

Then

Doctors gained a CLDN18.2 option for first-line patients, paired with chemotherapy.

Now

The approval confirmed CLDN18.2 as a real drug target, not just a research idea.

Why this matters now

Vyloy validated the target; Innovent's drug attacks the same protein with a stronger payload aimed at later-stage patients.

Sources

(6)
PR Newswire BioSpace RTTNews Nature Medicine Takeda U.S. Food and Drug Administration